Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

CartilaGen

CartilaGen
2014 FOUNDED
PRIVATE STATUS
Later Stage VC LATEST DEAL TYPE
4 INVESTORS
Description

Developer of cost-effective biological joint replacement intended to help orthopedic surgeons to perform several unique OA and cartilage repair techniques. The company offerings include drug-eluting biomaterials, disease-modifying therapeutics, and wearable drug delivery devices to treat knee osteoarthritis (OA), providing customers with better preventative treatment.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 25 south grand Avenue, 2192-2
  • Iowa City, IA 52246
  • United States
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore CartilaGen’s full profile, request a free trial.

CartilaGen Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC Completed Pre-Clinical Trials
3. Grant 02-May-2016 000 Completed Startup
2. Grant 30-Apr-2016 $5K Completed Startup
1. Grant 10-Apr-2016 $2K Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

CartilaGen Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Columbia University Graduate School of Business Other 000 0000 000000 0
The Chinese University of Hong Kong University 000 0000 000000 0
Harvard University Endowment Limited Partner 000 0000 000000 0
EGI Capital Venture Capital Minority 000 0000 000000 0

CartilaGen Executive Team (2)

Name Title Board
Seat
Contact
Info
Frank Yu Ph.D Co-Founder & Chief Executive Officer
Jaison Marks Co-Founder & Vice President